Isuzinaxib clinical trials
Also written APX-115.
How each study uses isuzinaxib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the isuzinaxib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Aptabio Therapeutics, Inc. (5)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test isuzinaxib.
- Jun 2027Efficacy and Safety Study of Isuzinaxib in Subjects With DKDPhase 2 · Aptabio Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses isuzinaxib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Efficacy and Safety Study of Isuzinaxib in Subjects With DKDRecruitingPhase 2Aptabio Therapeutics, Inc.NCT06962098Written as Isuzinaxib
- Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCICompletedPhase 2Aptabio Therapeutics, Inc.NCT05758896Written as Isuzinaxib (APX-115)
- A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.TerminatedPhase 2Aptabio Therapeutics, Inc.NCT04880109Written as APX-115
- Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and NephropathyCompletedPhase 2Aptabio Therapeutics, Inc.NCT04534439Written as APX-115
- Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male VolunteersCompletedPhase 1Aptabio Therapeutics, Inc.NCT03694041Written as SAD: APX-115
Codes
What other systems call isuzinaxib · ClinicalTrials.gg INT000726
- MeSH (NLM) C000620865isuzinaxibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YP664UDC7TISUZINAXIBConfirmed FDA, NLM
- NCI Thesaurus C179095IsuzinaxibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000620865 | isuzinaxib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YP664UDC7T | ISUZINAXIB | Confirmed FDA, NLM |
| NCI Thesaurus | C179095 | Isuzinaxib | One source FDA |
Also registered as isuzinaxib hydrochloride (UNII Q99G5ZE5U5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.